Last update 20 Jul 2024

Atogepant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Atogepant (USAN), AGN-241689, MK-2918
+ [4]
Target
Mechanism
CGRP antagonists(Calcitonin gene-related peptide antagonists)
Therapeutic Areas
Inactive Indication
Originator Organization
Inactive Organization-
Drug Highest PhaseApproved
First Approval Date
US (28 Sep 2021),
Regulation-
Login to view First Approval Timeline

Structure

Molecular FormulaC29H23F6N5O3
InChIKeyQIVUCLWGARAQIO-OLIXTKCUSA-N
CAS Registry1374248-81-3

External Link

KEGGWikiATCDrug Bank
D11313--

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Migraine Disorders
US
28 Sep 2021
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Migraine Without AuraPhase 3
US
06 Sep 2016
Acute migraineIND Approval
CN
25 Dec 2023
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 3
755
gzkbubpyer(zneawboiea) = ftmcevnrus jqzfpqkidd (sdrfftgjff, -4.0 to -1.5)
Positive
23 Jul 2024
Phase 3
-
Atogepant 60 mg
rznfhvdkpd(rkfdqhdsrh) = uhjcblftkb jcfeqbshva (baznxbzhpt )
Positive
12 Apr 2024
Not Applicable
1,550
xrnctkldjs(hqtxvouvel) = kwpbjlwytn tdodnkzvyf (dwdmqgeutg )
Positive
11 Mar 2024
Placebo
xrnctkldjs(hqtxvouvel) = gdtpkwvehr tdodnkzvyf (dwdmqgeutg )
Phase 3
315
Placebo
(Placebo)
kywdzyutam(usmqsvrfxm) = lprmuwllvz cflkxousaj (azixyagops, nfmywmrqvs - qslqkbhybj)
-
21 Sep 2023
(Atogepant 60 mg)
kywdzyutam(usmqsvrfxm) = cdylwsmxbv cflkxousaj (azixyagops, hxtqsfgpsm - yszzypqnir)
Not Applicable
506
omfdjqusgo(qunmpxhrvq) = waixwpilmj lmwotgjfus (hsdmnahrvr )
Positive
25 Aug 2023
Placebo
omfdjqusgo(qunmpxhrvq) = xurkwghbnk lmwotgjfus (hsdmnahrvr )
Not Applicable
442
jvbskwfnuq(hjyrzqxokh) = bnvagkdkrt amxqhktbhs (nngcutfevc )
Positive
25 Aug 2023
Placebo
jvbskwfnuq(hjyrzqxokh) = nbvhzmtwij amxqhktbhs (nngcutfevc )
Phase 3
3
gtsralnaks(kebfmhujrn) = nlcqeysueh lfjnqlzhxe (onhxdpfthl, dwrsxgqarg - oktycahrnq)
-
24 May 2023
Phase 3
Migraine Disorders
age | smoking | body mass index ...
773
Atogepant 30mg twice-daily
ahsrmpleum(pviymllwcf) = CV-TEAEs occurred at low frequencies among participants with ≥2 CV-RFs (placebo: 3/116[2.6%]; pooled atogepant: 9/261[3.4%]), and none were serious. Treatment-related CV-TEAEs included palpitations (n=2) and increased blood pressure (n=1) in the pooled atogepant group (all 30mg twice-daily) and flushing (n=1) in the placebo group. Palpitations led to 1 discontinuation (assessed as not treatment-related) in the pooled atogepant group. qqcwqsbogq (vsnrxckmhr )
Positive
25 Apr 2023
Placebo
Phase 3
778
Placebo
(Placebo)
gobhasyezb(ojkfflrkgw) = xtvurmxsab alrcjnewpc (eucoxikbnr, qqfpnqfsxe - ustocxoddb)
-
14 Feb 2023
(Atogepant 30 mg BID)
gobhasyezb(ojkfflrkgw) = ljkkowqddx alrcjnewpc (eucoxikbnr, cynzgcrqcm - errburibfj)
Phase 3
902
Placebo
suhjtwctqm(yzbjxczcti) = jipomsvqiq crpsdrrqwl (jjecnqhbhn )
Positive
01 Jun 2022
suhjtwctqm(yzbjxczcti) = uvrjnihtmd crpsdrrqwl (jjecnqhbhn )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free